Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)
Breast Cancer2001Vol. 8(4), pp. 316–320
Citations Over Time
Shinobu Umemura, Goi Sakamoto, Hironobu Sasano, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yutaka Tokuda, Toru Watanabe, Masakazu Toi, Tadashi Hasegawa, R. Yoshiyuki Osamura
Related Papers
- → Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer(2019)56 cited
- → Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer(2009)6 cited
- → Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing in breast cancer patients to maximize detection of her2/neu-positive patients and susceptability to Trastuzumab(2011)1 cited
- → Predictive value of serum HER2/neu ECD during trastuzumab-based therapy in patients with breast cancer(2002)
- → HTA166 Cost-Effectiveness of Combination Pertuzumab+Trastuzumab Vs Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer (HER2+ eBC) in the Czech Republic(2023)